<DOC>
	<DOCNO>NCT01340898</DOCNO>
	<brief_summary>This study evaluate immunogenicity safety meningococcal conjugate vaccine GSK 134612 healthy infant , co-administered infant vaccine , three different dose schedule .</brief_summary>
	<brief_title>Immunogenicity Safety Study GSK Biologicals ' Meningococcal Conjugate Vaccine When Co-administered With Routine Vaccines Healthy Infants Toddlers</brief_title>
	<detailed_description>This protocol update follow Protocol Amendment 1 date 26 July 2011 lead update enrollment , secondary outcome measure , intervention exclusion criterion section .</detailed_description>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe parent ( ) /Legally Acceptable Representative ( ) [ LAR ( ) ] comply requirement protocol . A male female , 6 12 week ( 4290 day ) age time first vaccination . Written inform consent obtain parent ( ) /LAR ( ) subject . Healthy subject establish medical history clinical examination enter study . Born gestation period least 36 week . Child care . Use investigational nonregistered product study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . Extended administration immunosuppressant immunemodifying drug since birth . Planned administration/administration vaccine foreseen study protocol period 30 day study vaccine administration , exception rotavirus vaccine seasonal pandemic influenza vaccine . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product . Previous vaccination diphtheria , tetanus , pertussis , polio ( exception birth dose OPV ) , Haemophilus influenzae type b , Streptococcus pneumonia . History receipt meningococcal vaccine . Subjects received birth dose Hepatitis B vaccine within 30 day administration first study vaccine . History intercurrent diphtheria , tetanus , pertussis , polio , Haemophilus influenzae type b disease , pneumococcal and/or meningococcal disease . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination ( laboratory testing require ) . Family history congenital hereditary immunodeficiency . History reaction hypersensitivity likely exacerbate component th</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>12 Weeks</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>meningococcal conjugate vaccine</keyword>
	<keyword>serogroups A , C , W-135 Y</keyword>
	<keyword>meningococcal disease</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Neisseria meningitidis</keyword>
	<keyword>co-administration</keyword>
	<keyword>routine vaccine</keyword>
</DOC>